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we estimate that there are more than
100000 patients presently on statin
treatment, and that about 10% of these
patients will also be on long-term
warfarin therapy. I believe your
Editorial was correct in highlighting the
issue of safety, and to suggest that
“physicians must tell their patients the
truth about rosuvastatin”. However, I
would add that physicians themselves
should be informed of the real risk of a
clinically significant interaction between
rosuvastatin and warfarin. Such a
combination should be avoided in my
view—alternative statin drugs can be
safely co-administered.
Michael Barry
Department of Pharmacology and Therapeutics,
Trinity College Dublin, Dublin 2, Ireland
(e-mail: mbarry@stjames.ie)
1 The Lancet. The statin wars: why
AstraZeneca must retreat. Lancet 2003; 362:
1341.
Author’s reply
Sir—To extricate politics from medical
journals—especially in a section
dedicated to health and human rights—
is wrong for at least five reasons. First,
medicine has a history of being
misapplied for politically motivated
ends. The human rights abuses
committed by physicians in the employ
of the Nazi and apartheid regimes speak
to this point.
Second, medical personnel some-
times practise in settings where the
infliction of politically motivated human
rights abuses is common. Apartheid
South Africa and present-day Zimbabwe
are examples of such settings.
Third, the opinion of medical
professionals carries substantial moral
and political clout in many quarters. If
convinced on an issue, this community
could use its leverage to lobby for
change in policy at a state level. This
strategy on AIDS treatment recently
bore fruit in South Africa.
Fourth, medical professionals are
involved in decision-making at the
highest political levels. South Africa’s
Foreign Minister, for example, is a
medical doctor. Cogent arguments in a
reputable journal, especially when such
views are endorsed by WHO,1 could
potentially influence such people to alter
or affirm their state’s foreign policies.
Finally, debate is healthy. It usually
results in better informed individuals
and policies. Medical journals,
especially reputable ones, thus have an
ethical duty to publish works that
consider the ramifications of political
decision-making on health and human
rights; more so if such works can
potentially realise a change in policy-
making that results in ameliorations in
these arenas for affected parties.
With respect to Jim Whiting’s second
point, I concur. Moreover, I believe that
criticism of such practices—particularly
given its detrimental effect on health and
human rights in affected countries—
should especially be voiced by those in
the developing world. Although I and
other colleagues from the developing
world recently voiced our opinion on
this issue,2 more need to join our call. As
we argued, corruption and self-serving
aggrandisement and oppression (among
e-mail submissions to correspondence@lancet.com
Rosuvastatin–warfarin drug interaction
Sir—In your Oct 25 Editorial (p 1341),1
you suggest that safety cannot be
assured for statin medications, and cite
the example of cerivastatin-associated
rhabdomyolysis and the fact that the 80
mg dose of rosuvastatin was withdrawn
by AstraZeneca because of safety
concerns. I would like to highlight the
clinically significant interaction between
rosuvastatin and warfarin, which has
received little attention to date.
The British National Formulary
suggests that the effect of warfarin is
“possibly enhanced” by rosuvastatin.
The summary of product characteristics
for rosuvastatin in Ireland suggests 
that concomitant administration of
rosuvastatin and warfarin “may result in
an increase in International Normalised
Ratio (INR)” and that “appropriate
monitoring of INR is desirable”. The
possibility of an interaction first came to
my attention from a report on an
adverse event from the continuing
JUPITER study, in which a 74-year-
old female patient on long-term 
warfarin developed increased bruising,
haematuria, and lightheadedness about
4 weeks after starting rosuvastatin. Her
INR was recorded at 8·0, having been
stable at 2·0 before the introduction of
the statin. The interaction resulted in
hospital admission, and treatment
included the discontinuation of
warfarin, 2 units fresh frozen plasma,
and 10 mg vitamin K. Most clinicians
would conclude that this was a clinically
significant interaction.
AstraZeneca have done at least two
clinical studies on the co-administration
of rosuvastatin and warfarin, and
presumably the results of these studies
provide the basis for the suggestion by
the British National Formulary that
there might be an interaction between
rosuvastatin and warfarin. Having
received details of the studies from
AstraZeneca, I am unable to outline the
findings here because a confidentiality
clause has been added.
Just how relevant is all this? We asked
more than 1700 general practitioners in
1999 about factors they regarded as
important in relation to prescription of
statins. The three most important
points according to the clinicians were
safety, efficacy, and drug interactions.
From our prescribing data in Ireland,
Politics in medical journals
Sir—I am dismayed by the appearance,
again, of a political tract by Jerome
Singh (Nov 15, p 1672),1 this time on
the necessity for rich nations to take
care of poor nations. If this had been
written 60 years ago, it would have
been justly decried as a defence for
colonialism. Justice and fairness were
used as justifications then, too.
If The Lancet is justified in devoting a
section to health and human rights—a
combination that should seem odder
than it does—it would be much more
helpful to elaborate on the plights of
the nations in reference—here Rwanda
and Sierra Leone—so as to address
root causes rather than pleas for alms.
If political issues need to be addressed
in a medical journal, surely that should
start with a critical description of the
corruption, lawlessness, extortion, and
criminal neglect that characterise these
countries. I appeal to the editors to
exercise the judgment we expect in a
journal of such pedigree.
Jim Whiting
Department of Imaging, Portland VA Medical
Center, Portland, OR 97207, USA
(e-mail: jimmww@yahoo.com)
1 Singh JA. Is donor aid allocation to Iraq
fair? Lancet 2003; 362: 1672.
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other practices) on the part of many
developing world leaders is having a
devastating effect on health services in
those countries. Here again, medical
journals have an ethical duty to publish
such opinions.
Affluent donor nations are making
noteworthy attempts to uplift conditions
in the developing world. The Fogarty
International Center of the US National
Institutes of Health, for example, is a
leading proponent of north-south
partnerships and southern capacity-
building in the medical arena. Whiting
perhaps missed the point of my paper. It
was not that rich donor nations are
obliged to donate aid to poorer nations;
rather, if they choose to do so they
should disburse their aid fairly so that
those most in need benefit. 
Works in reputable medical journals
can potentially influence policy-making
and ultimately affect millions of lives. I
applaud The Lancet for its boldness and
tenacity in covering politically sensitive
issues that concern health and human
rights.
Jerome A Singh
Howard College School of Law, University of
Natal, Durban 4041, South Africa
(e-mail: singhj9@nu.ac.za)
1 Nabarro D, Loretti A, Colombo A. Increased
equity in postconflict reconstruction. Lancet
2003; 362: 1673.
2 Singh JA, Nkala B, Amuah E, Mehta N,
Ahmad A. The ethics of nurse-poaching from
the developing world. Nursing Ethics 2003;
10: 667–71.
none in fact deal with human rights but
instead with social justice and ethical
concerns. Those working in the fields of
ethics, human rights, and social justice
are learning where our fields converge,
overlap, and complement one another,
but our differences are also important
because they define a powerful synergy,
rather than redundancy, among these
fields.
Traditionally, human rights issues are
meant in the first instance to guide the
actions of governments, whereas ethics
much more broadly encompasses
concern for the specific actions and
relationships of individual health
workers, researchers, and organisations.
The ethical principles that guide our
work are the product of broad-based
consultation and are presented in the
form of guidelines and proposed codes
of conduct by professional bodies and
organisations. Human rights norms and
standards tend to be drafted by
government representatives, negotiated
in political fora, and incorporated in the
body of international law in the form of
international treaties which impose legal
obligations on the governments that
ratify them. Although each piece
presented is certainly worthy of
publication, I fear that their placement
within this section will only serve to
confuse the public health community as
to the value of human rights, ethics, and
social justice for public health work. Our
work requires attention to the distinct
value of each and the differences in the
paradigms they represent. We should
support these differences, but we also
should not obscure them. The Lancet, by
promoting a section entitled Health and
Human Rights, also has a responsibility
in this regard.
Sofia Gruskin
Program on International Health and Human
Rights, François-Xavier Bagnoud Center for
Health and Human Rights, Harvard School of
Public Health, 651 Huntington Avenue, Boston,
MA 02115, USA
(e-mail: sgruskin@hsph.harvard.edu)
What are health and human
rights?
Sir—The inclusion in The Lancet over
the past several years of a regular section
entitled Health and Human Rights has
brought useful and timely pieces to a
diverse audience, and has helped signal
wider recognition of this field.
Until recently, all the pieces have in
one way or another drawn out the
human rights implications of health
policy and practice. Although some of
these pieces have been skewed towards
the health effects of civil and political
rights violation—in particular torture—
with insufficient attention to the
implication of economic and social
rights for health, or the effects of
attention to human rights on public
health programming, all have displayed
understanding of human rights
principles, methods, or instruments.
All the more disappointing, therefore,
to be confronted with the Health and
Human Rights section in your Sept 20
and Nov 15 issues. Although the pieces
are to be commended on their own
merit, and each is timely and interesting,
Quality of medical
education in Mexico
Sir—We agree with Julio Frenk and
colleagues (Nov 15, p 1667),1 that
substantial advancements have been
made in the Mexican health system. We
believe that the proposed structure of
the National Health Program will
improve the health of the Mexican
people, especially the most vulnerable.
Frenk and colleagues mention that
the National Crusade of the Quality of
Health Services was launched to
increase the effectiveness and
responsiveness of health services by
promoting the certification of health
professionals and the use of clinical
guidelines, and by improving access to
evidenced-based resources. To achieve
this end, we think that changing the way
physicians are trained and taught is
paramount.
According to the WHO, Mexico has
56 medical schools, from which about
7800 physicians graduate each year.
This term, 21 235 physicians competed
for 4625 residency spots by undergoing
an examination. Results of this
examination are kept private, and the
general public are not informed of how
medical schools rank in terms of
outcome in this test. Those who are
successful must apply to their hospital of
preference, which then keeps their
papers and makes a decision on whether
or not they are accepted. This process
limits the physician to applying to only
one or two institutions, and needless to
say benefits the institutions more than
the trainees.
Residency training in Mexico is done
by following a very strict hierarchical
pattern, teaching is scarce, and residents
learn mostly by imitation rather than
evidence-based medicine. Training is
done under conditions of stress, long
hours of work, and poor pay.
Evidence2 suggests that Mexican
physicians in training are poor at
critically reading clinical research. In
one report, 572 residents from different
specialties were assessed on their
abilities to judge and interpret clinical
research. Scores were low, with
medians of less than 34%. 17–28% of
examinees scored less than they would
have if they had answered randomly.2,3
In another report, the level of training
residents received did not affect their
performance in this test.4 Clearly these
findings cannot be applied to all
Mexican medical residents, but the lack
of research in this area leads us to
believe that they could be a good
indicator.
Furthermore, Villasis-Keever and
colleagues5 analysed the seroprevalence
of hepatitis B in residents in one
institution, and concluded that only
80% had been vaccinated, of whom only
41·6% had completed the course. If
these physicians do not understand the
importance of preventive medicine, how
can they possibly teach and practise it
on their patients?
Although the main focus of Frenk and
colleagues’ article is based on health
policies rather than education, we
believe that medical education in
Mexico has to be reformed, and that
teaching in institutions, medical schools,
and residency programmes must be
standardised and certified. This
standardisation will greatly improve the
